Despite Amicus Therapeutics' recent share price uptick and s...
Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.
Strong Week for Amicus Therapeutics (NASDAQ:FOLD) Shareholders Doesn't Alleviate Pain of Three-year Loss
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4955
Followers
0
Following
11K
Visitors
Follow